We investigated whether loss of BRCC3 renders Kasumi-1 cells more sensitive towards doxorubicin and cytarabine that are the standard treatment for AML with t(8;21)(q22;q22.1). The gene discussed is BRCC3; the disease is acute myeloid leukemia.